Clinical Trial Update: A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 study evaluating resistance and durability of response for ABT-493 and ABT-530 in Hepatitis C has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493
• ABT-530

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-09-21